Literature DB >> 26661222

Pharmacologic manipulation of lysosomal enzyme transport across the blood-brain barrier.

Akihiko Urayama1, Jeffrey H Grubb2, William S Sly3, William A Banks4.   

Abstract

The adult blood-brain barrier, unlike the neonatal blood-brain barrier, does not transport lysosomal enzymes into brain, making enzyme replacement therapy ineffective in treating the central nervous system symptoms of lysosomal storage diseases. However, enzyme transport can be re-induced with alpha-adrenergics. Here, we examined agents that are known to alter the blood-brain barrier transport of large molecules or to induce lysosomal enzyme transport across the blood-brain barrier ((±)epinephrine, insulin, retinoic acid, and lipopolysaccharide) in 2-week-old and adult mice. In 2-week-old adolescent mice, all these pharmacologic agents increased brain and heart uptake of phosphorylated human β-glucuronidase. In 8-week-old adult mice, manipulations with (±)epinephrine, insulin, and retinoic acid were significantly effective on uptake by brain and heart. The increased uptake of phosphorylated human β-glucuronidase was inhibited by mannose 6-phosphate for the agents (±)epinephrine and retinoic acid and by L-NG-nitroarginine methyl ester for the agent lipopolysaccharide in neonatal and adult mice. An in situ brain perfusion study revealed that retinoic acid directly modulated the transport of phosphorylated human β-glucuronidase across the blood-brain barrier. The present study indicates that there are multiple opportunities to at least transiently induce phosphorylated human β-glucuronidase transport at the adult blood-brain barrier.
© The Author(s) 2015.

Entities:  

Keywords:  Blood–brain barrier; brain uptake; enzyme replacement therapy; mannose 6-phosphate receptor; β-glucuronidase

Mesh:

Substances:

Year:  2015        PMID: 26661222      PMCID: PMC4794098          DOI: 10.1177/0271678X15614589

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  38 in total

1.  Enzyme replacement therapy in a mouse model of aspartylglycosaminuria.

Authors:  U Dunder; V Kaartinen; P Valtonen; E Väänänen; V M Kosma; N Heisterkamp; J Groffen; I Mononen
Journal:  FASEB J       Date:  2000-02       Impact factor: 5.191

2.  Ligand interactions of the cation-independent mannose 6-phosphate receptor. The stoichiometry of mannose 6-phosphate binding.

Authors:  P Y Tong; W Gregory; S Kornfeld
Journal:  J Biol Chem       Date:  1989-05-15       Impact factor: 5.157

3.  Ligand interactions of the cation-dependent mannose 6-phosphate receptor. Comparison with the cation-independent mannose 6-phosphate receptor.

Authors:  P Y Tong; S Kornfeld
Journal:  J Biol Chem       Date:  1989-05-15       Impact factor: 5.157

Review 4.  Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges.

Authors:  R J Desnick; E H Schuchman
Journal:  Annu Rev Genomics Hum Genet       Date:  2012       Impact factor: 8.929

Review 5.  Endocytosis of receptor tyrosine kinases.

Authors:  Lai Kuan Goh; Alexander Sorkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-05-01       Impact factor: 10.005

6.  Clearance of albumin from mouse subarachnoid space: a measure of CSF bulk flow.

Authors:  R A Rudick; D K Zirretta; R M Herndon
Journal:  J Neurosci Methods       Date:  1982-09       Impact factor: 2.390

7.  β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.

Authors:  Dwight D Koeberl; Songtao Li; Jian Dai; Beth L Thurberg; Deeksha Bali; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2011-11-11       Impact factor: 4.797

8.  Transport of arylsulfatase A across the blood-brain barrier in vitro.

Authors:  Frank Matthes; Philipp Wölte; Annika Böckenhoff; Sabine Hüwel; Mareike Schulz; Pia Hyden; Jens Fogh; Volkmar Gieselmann; Hans-Joachim Galla; Ulrich Matzner
Journal:  J Biol Chem       Date:  2011-03-28       Impact factor: 5.157

9.  Glucose and insulin increase the transport of leptin through the blood-brain barrier in normal mice but not in streptozotocin-diabetic mice.

Authors:  A J Kastin; V Akerstrom
Journal:  Neuroendocrinology       Date:  2001-04       Impact factor: 4.914

10.  Enzyme replacement with recombinant beta-glucuronidase in the newborn mucopolysaccharidosis type VII mouse.

Authors:  C Vogler; M Sands; A Higgins; B Levy; J Grubb; E H Birkenmeier; W S Sly
Journal:  Pediatr Res       Date:  1993-12       Impact factor: 3.756

View more
  7 in total

1.  Modifying blood-brain barrier transport to bring hope for patients with lysosomal storage diseases.

Authors:  Richard F Keep; Jianming Xiang
Journal:  J Cereb Blood Flow Metab       Date:  2015-11-04       Impact factor: 6.200

2.  Guanidinylated Neomycin Conjugation Enhances Intranasal Enzyme Replacement in the Brain.

Authors:  Wenyong Tong; Chrissa A Dwyer; Bryan E Thacker; Charles A Glass; Jillian R Brown; Kristina Hamill; Kelley W Moremen; Stéphane Sarrazin; Philip L S M Gordts; Lara E Dozier; Gentry N Patrick; Yitzhak Tor; Jeffrey D Esko
Journal:  Mol Ther       Date:  2017-08-12       Impact factor: 11.454

Review 3.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

4.  miR-143 Regulates Lysosomal Enzyme Transport across the Blood-Brain Barrier and Transforms CNS Treatment for Mucopolysaccharidosis Type I.

Authors:  Yi Lin; Xiaohong Wang; Kevin P Rose; Mei Dai; Jingfen Han; Mei Xin; Dao Pan
Journal:  Mol Ther       Date:  2020-06-15       Impact factor: 11.454

Review 5.  Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications.

Authors:  Alessandra Biffi
Journal:  Mol Ther       Date:  2017-04-04       Impact factor: 11.454

Review 6.  The blood-brain barrier as an endocrine tissue.

Authors:  William A Banks
Journal:  Nat Rev Endocrinol       Date:  2019-08       Impact factor: 43.330

7.  Participation of Monocarboxylate Transporter 8, But Not P-Glycoprotein, in Carrier-Mediated Cerebral Elimination of Phenytoin across the Blood-Brain Barrier.

Authors:  Ryuta Jomura; Shin-Ichi Akanuma; Björn Bauer; Yukiko Yoshida; Yoshiyuki Kubo; Ken-Ichi Hosoya
Journal:  Pharm Res       Date:  2021-02-01       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.